Cart
sales@molnova.com
Fosciclopirox
CAS No. 1380539-06-9
Fosciclopirox( CPX-POM )
Catalog No. M28675 CAS No. 1380539-06-9
Fosciclopirox, the phosphoryloxymethyl ester of CPX (Ciclopirox Prodrug, CPX-POM), selectively delivers the active metabolite, CPX, to the entire urinary tract following parenteral administration.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 43 | Get Quote |
|
| 5MG | 72 | Get Quote |
|
| 10MG | 125 | Get Quote |
|
| 25MG | 260 | Get Quote |
|
| 50MG | 410 | Get Quote |
|
| 100MG | 606 | Get Quote |
|
| 500MG | 1287 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameFosciclopirox
-
NoteResearch use only, not for human use.
-
Brief DescriptionFosciclopirox, the phosphoryloxymethyl ester of CPX (Ciclopirox Prodrug, CPX-POM), selectively delivers the active metabolite, CPX, to the entire urinary tract following parenteral administration.
-
DescriptionFosciclopirox, the phosphoryloxymethyl ester of CPX (Ciclopirox Prodrug, CPX-POM), selectively delivers the active metabolite, CPX, to the entire urinary tract following parenteral administration.
-
In Vitro——
-
In Vivo——
-
SynonymsCPX-POM
-
PathwayNeuroscience
-
TargetGamma-secretase
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1380539-06-9
-
Formula Weight317.278
-
Molecular FormulaC13H20NO6P
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (315.19 mM)
-
SMILESCc1cc(C2CCCCC2)n(OCOP(O)(O)=O)c(=O)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Faria DB, et al. Effects of lidocaine and droxicainide on myocardial necrosis: a comparative study. J Am Coll Cardiol. 1983 Jun;1(6):1447-52.
molnova catalog
related products
-
CB-103
CB-103 is a orally active inhibitor of notch signaling pathway, with anti-tumor activity. CB-103 has shown the ability to block NOTCH signaling in human T cell acute lymphoblastic leukemia cancer cell lines, and?exhibits anti-tumor efficacy in GSI resistant T-ALL cell lines.
-
Brontictuzumab
Brontictuzumab (OMP 52M5) is a monoclonal antibody that targets Notch1 and inhibits activation of the pathway.
-
LY900009
LY900009 is a small molecule inhibitor of Notch signalling via selective inhibition of the γ-secretase protein.?
